In short
Clinical trials are investigating Lna043 in people with symptomatic knee osteoarthritis. These studies are checking safety, tolerability, and whether Lna043 can improve knee structure compared with placebo. The main target population is adults with painful knee osteoarthritis.
Key points
- Lna043 is being studied in clinical trials for symptomatic knee osteoarthritis. The main trial in the source data is a Phase 2 interventional study with 581 participants. Researchers compared Lna043 with placebo to see whether it could improve knee structure over time. The study also assessed safety and tolerability. The main outcome was change from baseline in the knee structure of the target knee, especially in the central medial tibiofemoral compartment. The trial has been completed.
Trial overview
The source data includes one interventional study of Lna043 in people with symptomatic knee osteoarthritis. It was a Phase 2 trial, which means it was designed to look for early signs of benefit while also checking safety and tolerability.
Who participated
The study population was patients with osteoarthritis, specifically symptomatic knee osteoarthritis. The trial data do not list more detailed eligibility rules, but the study clearly focused on people with symptoms in the knee.
What was studied
Researchers studied Lna043 as a drug given by intraarticular use, which means it was used inside the joint. The trial compared Lna043 with placebo, which is a look-alike treatment with no active study drug. The main goal was to see whether Lna043 could improve knee structure in the target knee.
Outcomes measured
The primary outcome was change from baseline in the knee structure. More specifically, the study looked at the central medial tibiofemoral compartment, a part of the knee joint on the inner side where the thigh bone and shin bone meet. The brief summary says this outcome was measured at Week 104, showing that the study followed patients for a long period.
Trial status and size
The study is listed as completed. It enrolled 581 participants, which makes it a fairly large Phase 2 study for a knee osteoarthritis trial.
What the results focused on
The trial focused on three main questions: whether Lna043 was safe, whether people could tolerate it, and whether it changed knee structure better than placebo. Because the data provided here are trial details rather than final results, the article can describe the study goals and measurements, but not a full outcome report.